Refine
Has Fulltext
- yes (13)
Is part of the Bibliography
- yes (13)
Document Type
- Journal article (13) (remove)
Language
- English (13) (remove)
Keywords
- gene expression (3)
- thymus (2)
- Activation (1)
- B cell malignancies (1)
- Breast-cancer (1)
- CD/metabolism (1)
- CD40 ligand (1)
- Cancer (1)
- DNA hypermethylation (1)
- DNA methylation (1)
- Defined burkitts lymphoma (1)
- Expression (1)
- FFPE (1)
- Fak regulation (1)
- Gene-expression (1)
- Genome wide analysis (1)
- Hans algorithm (1)
- High-resolution (1)
- Histone deacetylase inhibition (1)
- Hodgkin lymphoma (1)
- Induced apoptosis (1)
- LESA (1)
- Lung-cancer (1)
- Lymph2Cx assay (1)
- MTCH2 (1)
- Mantle cell lymphoma (1)
- Mechanisms (1)
- Microarray (1)
- Migration (1)
- Molecular pathogenesis (1)
- Multiple (1)
- NF-Kappa-B (1)
- NGS (1)
- Nuclear expression (1)
- Pathogenesis (1)
- Phase- (1)
- Promoter (1)
- Rituximab plus (1)
- Riutximab (1)
- Sox9 (1)
- Stromal cells (1)
- Survival (1)
- T-cell lymphoma (1)
- Targets (1)
- Transcription-factor (1)
- abnormalities (1)
- amplifications (1)
- antigens (1)
- apoptosis (1)
- autoimmune disease (1)
- c-myc (1)
- cell of origin (1)
- cyclophsophamide (1)
- deletions (1)
- diagnostics (1)
- diffuse large B-cell lymphoma (1)
- distinct (1)
- flow cytometry (1)
- follicular lymphoma (1)
- gene regulation (1)
- genomic aberrations (1)
- grade 3B (1)
- growth patterns (1)
- high numbers (1)
- imaging (1)
- in-vitro (1)
- independent predictor (1)
- individual drug responses (1)
- lymphoma (1)
- machine learning (1)
- mantel cell lymphoma (1)
- marcophages (1)
- molecular subtypes (1)
- mouse xenografts (1)
- mutation (1)
- myasthenia (1)
- myasthenia gravis (1)
- ovarian tumor (1)
- panel-sequencing (1)
- pathology (1)
- perfusion culture (1)
- personalized medicine (1)
- poor prognosis (1)
- precision-cut tumor slices (1)
- preclinical model (1)
- prognostic factor (1)
- regulatory T-cells (1)
- relapse (1)
- surgery (1)
- survival (1)
- targeted (1)
- thymic carcinoma (1)
- thymic epithelial tumor (1)
- thymitis (1)
- thymoma (1)
- transformation (1)
- tumor heterogeneity (1)
- tumor microenvironment (1)
Recent studies have shown aberrant expression of SOX11 in various types of aggressive B-cell neoplasms. To elucidate the molecular mechanisms leading to such deregulation, we performed a comprehensive SOX11 gene expression and epigenetic study in stem cells, normal hematopoietic cells and different lymphoid neoplasms. We observed that SOX11 expression is associated with unmethylated DNA and presence of activating histone marks (H3K9/14Ac and H3K4me3) in embryonic stem cells and some aggressive B-cell neoplasms. In contrast, adult stem cells, normal hematopoietic cells and other lymphoid neoplasms do not express SOX11. Such repression was associated with silencing histone marks H3K9me2 and H3K27me3. The SOX11 promoter of non-malignant cells was consistently unmethylated whereas lymphoid neoplasms with silenced SOX11 tended to acquire DNA hypermethylation. SOX11 silencing in cell lines was reversed by the histone deacetylase inhibitor SAHA but not by the DNA methyltransferase inhibitor AZA. These data indicate that, although DNA hypermethylation of SOX11 is frequent in lymphoid neoplasms, it seems to be functionally inert, as SOX11 is already silenced in the hematopoietic system. In contrast, the pathogenic role of SOX11 is associated with its de novo expression in some aggressive lymphoid malignancies, which is mediated by a shift from inactivating to activating histone modifications.
Diagnosing any of the more than 30 types of T-cell lymphomas is considered a challenging task for many pathologists and currently requires morphological expertise as well as the integration of clinical data, immunophenotype, flow cytometry and clonality analyses. Even considering all available information, some margin of doubt might remain using the current diagnostic procedures. In recent times, the genetic landscape of most T-cell lymphomas has been elucidated, showing a number of diagnostically relevant mutations. In addition, recent data indicate that some of these genetic alterations might bear prognostic and predictive value. Extensive genetic analyses, such as whole exome or large panel sequencing are still expensive and time consuming, therefore limiting their application in routine diagnostic. We therefore devoted our effort to develop a lean approach for genetic analysis of T-cell lymphomas, focusing on maximum efficiency rather than exhaustively covering all possible targets. Here we report the results generated with our small amplicon-based panel that could be used routinely on paraffin-embedded and even decalcified samples, on a single sample basis in parallel with other NGS-panels used in our routine diagnostic lab, in a relatively short time and with limited costs. We tested 128 available samples from two German reference centers as part of our routine work up (among which 116 T-cell lymphomas), which is the largest routine diagnostic series reported to date. Our results showed that this assay had a very high rate of technical success (97%) and could detect mutations in the majority (79%) of tested T-cell lymphoma samples.
Chromosomal translocations affecting the MYC oncogene are the biological hallmark of Burkitt lymphomas but also occur in a subset of other mature B-cell lymphomas. If accompanied by a chromosomal break targeting the BCL2 and/or BCL6 oncogene these MYC translocation-positive (MYC+) lymphomas are called double-hit lymphomas, otherwise the term single-hit lymphomas is applied. In order to characterize the biological features of these MYC+ lymphomas other than Burkitt lymphoma we explored, after exclusion of molecular Burkitt lymphoma as defined by gene expression profiling, the molecular, pathological and clinical aspects of 80 MYC-translocation-positive lymphomas (31 single-hit, 46 double-hit and 3 MYC+-lymphomas with unknown BCL6 status). Comparison of single-hit and double-hit lymphomas revealed no difference in MYC partner (IG/non-IG), genomic complexity, MYC expression or gene expression profile. Double-hit lymphomas more frequently showed a germinal center B-cell-like gene expression profile and had higher IGH and MYC mutation frequencies. Gene expression profiling revealed 130 differentially expressed genes between BCL6(+)/MYC+ and BCL2(+)/MYC+ double-hit lymphomas. BCL2(+)/MYC+ double-hit lymphomas more frequently showed a germinal center B-like gene expression profile. Analysis of all lymphomas according to MYC partner (IG/non-IG) revealed no substantial differences. In this series of lymphomas, in which immunochemotherapy was administered in only a minority of cases, single-hit and double-hit lymphomas had a similar poor outcome in contrast to the outcome of molecular Burkitt lymphoma and lymphomas without the MYC break. Our data suggest that, after excluding molecular Burkitt lymphoma and pediatric cases, MYC+ lymphomas are biologically quite homogeneous with single-hit and double-hit lymphomas as well as IG-MYC and non-IG-MYC+ lymphomas sharing various molecular characteristics.